Detalhe da pesquisa
1.
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.
Future Oncol
; 18(23): 2537-2550, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35678621
2.
Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.
Biomedicines
; 12(3)2024 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38540148
3.
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.
Vaccines (Basel)
; 11(6)2023 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37376406
4.
Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting.
Cancer Treat Res Commun
; 25: 100201, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32979704